Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Oral ST1481 Administered Once Weekly Every 3 Out 4 Weeks in Patients With Advanced Solid Malignancies.

NCT00033202 is registered in ClinicalTrials.gov with Sigma-Tau Research, Inc. as lead sponsor.

NCT NCT00033202
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00033202 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Oral ST1481 Administered Once Weekly Every 3 Out 4 Weeks in Patients With Advanced Solid Malignancies.
Lead sponsor
Sigma-Tau Research, Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2002
Completion date
February 28, 2005
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

solid malignancies